Ensign Group

ENSG · NASDAQ

$176.00+$2.95 (+1.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $173.05

ENSG analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $224.87 (+27.8% upside)

Low: $209.07
Now: $176.00
High: $241.50

Upgrades and downgrades

The latest rating actions, newest first

ENSG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Jul 30, 2026	Maintains	Hold	$202.00 → $207.00	67%
Truist Securities	Jul 14, 2026	Maintains	Hold	$215.00 → $202.00	67%
RBC Capital	Feb 9, 2026	Maintains	Outperform	$206.00 → $222.00	57%
Truist Securities	Feb 6, 2026	Maintains	Hold	$200.00 → $215.00	67%
RBC Capital	Nov 14, 2025	Maintains	Outperform	$177.00 → $206.00	57%
Truist Securities	Nov 10, 2025	Maintains	Hold	$190.00 → $200.00	67%
UBS	Nov 5, 2025	Maintains	Buy	$205.00 → $220.00	64%
Stephens & Co.	Nov 5, 2025	Maintains	Overweight	$185.00 → $200.00	71%

The case for and against

Updated Jul 28, 2026

Bull case

Ensign Group is well positioned to continue its strong financial performance, as demonstrated by its solid 2026 guidance, which exceeded both analyst and consensus expectations. Its unique M&A strategy and strong financial flexibility further support its growth initiatives, while its local structure and deep bench of AITs contribute to its strong operational momentum. Although there are potential risks such as exposure to government reimbursement and labor shortages, the company's diverse portfolio and successful acquisition track record provide a balanced outlook for Ensign Group's stock.

Bear case

Ensign Group is facing headwinds in the post-acute healthcare industry due to increasing competition and declining reimbursement rates from Medicare and Medicaid. The company's high level of debt, with an adjusted net debt to EBITDA ratio of 1.77x, also poses a risk to their financial stability. While management is optimistic about the potential for organic growth and has a strong acquisition strategy, there are concerns about their ability to execute these plans successfully.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.